News
Company News: Neonatal Diagnostics Company InfanDx Closesx Interim Financing Round
— Funding allows further advancement of lead product and achievement of key near-term milestones
InfanDx AG (Cologne, Germany), a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced the closing of an interim financing round involving both existing and new investors. The proceeds from this funding round are expected to provide the financial runway to achieve certain value-creating near-term milestones in clinical biomarker research for the Company’s lead product, the HypoxE test®. Further details of the financing round were not disclosed.
Company News: BellaSeno and Fraunhofer Institute for Production Technology IPT Receive EUR 1.4 Million BMBF Grant
— Funding dedicated to the development of commercial-scale, fully automated additive manufacturing of resorbable medical implants
— First-ever industrial-scale, additive manufacturing platform of medical implants
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, and the Fraunhofer Institute for Production Technology IPT today announced that both parties have received a grant totaling EUR 1.4 million from Germany´s Federal Ministry of Education and Research (BMBF) under the funding program KMU-innovativ.
Company News: SEQ-IT Reports Breakthrough in the Rapid Variant Diagnosis of SARS-CoV-2
SEQ-IT, a leading molecular services provider, today announced they completed a novel mass spectrometry based rapid test for the detection of 20 of the most relevant SARS-CoV-2 mutations including the UK (B.1.1.7), South African and Brazilian variants. The test panel was developed using Agena Bioscience’s MassARRAY® System, a well-established tool used by clinical laboratories worldwide to deliver affordable, highly accurate genomic testing.
Company News: Cardior’s pioneering miRNA approach in heart failure endorsed by expert opinions in the European Heart Journal
— First-ever development of an RNA therapeutic for heart failure
— Successful translation of unique scientific discovery into first-in-class clinical program
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that the Phase Ib results as well as preclinical and large-animal data of the Company’s lead compound CDR132L were published alongside with two editorials from independent experts in the European Heart Journal Volume 42, Issue 3, January 14, 2021, an issue focusing on ischemic heart diseases.
Cardior’s CDR132L: First-ever RNA-therapeutic addressing cardiovascular diseases advanced into the clinic Read more…